Loading…
Pharmaceutical company developing specialty biopharmaceuticals for nephrology, oncology and rare diseases.
Pharmaceutical company developing specialty biopharmaceuticals for nephrology, oncology and rare diseases.
Earns from drugs it sells itself in Japan, notably in kidney disease, and from specialty medicines sold abroad such as Crysvita, a rare bone-disease antibody shared with Ultragenyx. Milestone and royalty payments from partners add to this. Kirin Holdings, the beverage group, holds the majority.
In one line: A specialty biopharma like a smaller Alexion.
Moat: narrow (IP / patents, regulatory licence). Patent-protected specialty biologics in niche therapeutic areas with high regulatory barriers.
Headquarters: Tokyo, Japan · Founded: 1949 · Employees: 5,161
Size Kyowa Kirin (4151.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $8.05B, the 163rd largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥2,427 on 6 Nov 2026.
Performance Over six months the shares gained 4.2%, against +14.2% for the median peer and +1.8% for the Japan market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 10.4% over the last twelve months (peer median +12.6%); the operating margin is 24.3% (peer median 16.2%).
Valuation It trades at 15.6× forward earnings against a peer median of 24.3× (6th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.7 points above its cost of capital (6.3% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥532B | ¥497B | ¥496B | ¥442B | ¥398B |
| Revenue growth | — | 0% | +12% | +11% | — |
| Gross profit | ¥389B | ¥356B | ¥351B | ¥321B | ¥301B |
| EBITDA | ¥160B | ¥128B | ¥117B | ¥117B | ¥101B |
| Net income | ¥86.1B | ¥67.0B | ¥59.9B | ¥81.2B | ¥53.6B |
| Free cash flow | ¥73.7B | ¥58.9B | ¥41.8B | ¥98.3B | ¥33.1B |
| Capital expenditure | ¥77.2B | ¥83.5B | ¥105B | ¥32.9B | ¥28.7B |
| Total debt | ¥19.5B | ¥26.1B | ¥21.7B | ¥24.2B | ¥23.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kyowa Kirin 4151.T | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% |
| Chugai Pharmaceutical 4519.T | $71.0B | -15% | +17% | 50% | 22.1× | 3.6% |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 18.3× | 14.5% |
| Astellas Pharma 4503.T | $28.2B | +11% | +19% | 23% | 11.6× | -11.0% |
| Takeda Pharmaceutical 4502.T | $66.4B | +24% | +6% | 18% | 42.1× | 3.0% |
| Daiichi Sankyo 4568.T | $31.9B | +7% | +17% | 13% | 18.6× | 7.2% |
| Eisai 4523.T | $8.68B | +4% | +7% | 5% | 24.2× | 11.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4151.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.4% | +3.2% | 8th highest of 21 |
| 6-month return | +4.2% | +14.2% | 10th lowest of 21 |
| Distance from 52-week high | -15.5% | -11.3% | 10th lowest of 21 |
| Revenue growth (TTM) | +10.4% | +12.6% | 11th highest of 21 |
| Operating margin | 24.3% | 16.2% | 3rd highest of 20 |
| Forward P/E | 15.6× | 24.3× | 6th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -6.1% | 12.6% | 4th least demanding of 15 |
| Growth delivered (Del g) | +9.3% | +9.0% | 8th highest of 15 |
| Hurdle (Req g minus delivered) | -15.5 pp | -2.6 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +6.7 pp | +1.7 pp | 8th highest of 19 |
| EV / EBITDA | 6.6× | 20.8× | 2nd cheapest of 13 |
| Net debt / EBITDA | -1.4× | 0.8× | 4th least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% | +9.3% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $8.07B | +23% | +18% | 17% | 41.4× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | n/a | -9.1% | +6.6% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% | +12.6% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 11.4× | -10.0% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $8.69B | -10% | +10% | 6% | 10.4× | 20.5% | +5.8% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% | +10.8% |